A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
Kian JalaleddiniRobert A BermelBari TalenteDavid WeinsteinFerhan QureshiMaital RasmussenSreeranjani MenonMiyuru AmarapalaKesshi JordanAti GhoreyshiShannon McCurdyMike EdgeworthPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
While there are increased clinical and cost benefits as more eligible patients attempt discontinuation, the risk of relapses can increase. Timely disease monitoring is required to manage safe DMT discontinuation.
Keyphrases
- disease activity
- multiple sclerosis
- rheumatoid arthritis
- end stage renal disease
- systemic lupus erythematosus
- rheumatoid arthritis patients
- healthcare
- chronic kidney disease
- ejection fraction
- newly diagnosed
- ankylosing spondylitis
- public health
- peritoneal dialysis
- juvenile idiopathic arthritis
- mental health
- prognostic factors
- risk assessment
- patient reported outcomes
- health information